Chemours (CC) shares plummeted 6.86% in after-hours trading on Thursday, following the release of the company's fourth-quarter and full-year 2025 financial results.

The sharp decline was driven by the company reporting earnings and sales that fell short of analyst expectations. For the fourth quarter, Chemours posted adjusted earnings per share of $0.05, missing the consensus estimate of $0.07. Quarterly sales of $1.300 billion also came in below the estimated $1.328 billion. Furthermore, the company reported a net loss attributable to shareholders of $47 million for the quarter, a significant increase from the $11 million loss a year earlier.

For the full year 2025, the company's adjusted EBITDA of $742 million slightly missed the estimate of $755.2 million, while adjusted EPS of $0.95 was just below the $0.96 forecast. Looking ahead, Chemours provided guidance for fiscal year 2026, projecting net sales growth of 3% to 5% and adjusted EBITDA in the range of $800 million to $900 million.